Multiple sclerosis (MS) is a chronic, incurable, inflammatory disease of the central nervous system. In the United States, several Food and Drug Administration (FDA)-approved diseasemodifying treatments (DMTs) are available, including glatiramer acetate (GA; Copaxone ® ), one of the most longstanding treatments. GA was discovered serendipitously in the late 1960s/early 1970s while attempting to produce a synthetic antigen capable of inducing experimental autoimmune encephalomyelitis (EAE), an animal model of autoimmune inflammatory CNS disorders, including MS. Instead, GA was found to be protective in EAE models. Subsequent clinical evaluations resulted in GA's FDA approval for relapsing-remitting MS in 1996, followed by a change to the current indication of relapsing-forms of MS along with approval of a higher dose and less frequently administered version in 2014. The cost of DMTs including GA remains high, highlighting the potential value of generic therapies for MS. A rigorous scientific approach may be undertaken to demonstrate equivalence between the generic and innovator drug. The introduction of generic versions of GA into the MS treatment landscape has the potential to reduce treatment costs, improving access to these much-needed treatments.
Introduction
Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system (CNS) that affects approximately 400,000 individuals in the United States (US) [1] . Relapsing forms of MS include relapsing-remitting MS (RRMS) and secondary-progressive MS [1] [2] [3] , with 85% of patients having an initial diagnosis of RRMS [2, [4] [5] [6] . RRMS is characterized by acute attacks (also known as exacerbations or relapses) of new or worsening symptoms (i.e., neurological dysfunction) with periods of remission (partial or complete) between each relapse [5] [6] [7] .
Although preventative or curative treatments for relapsing forms of MS do not exist [8] , 
, and daclizumab (Zinbryta ® ) [9] [10] [11] [12] .
Given that MS is a chronic, progressive neurologic disorder with no cure, management of the disease requires the early initiation of lifelong treatment with DMTs that are well tolerated by the patient [8, 13] . However, the cost of DMTs remains high in the US despite the availability of multiple treatment options [9, 14] . The synthetic analogue, GA (Copaxone ® ), was one of the first FDA-approved DMTs (1996) for the treatment of RRMS [15] , and remains a valuable treatment option with two decades of clinical experience in the "real-world" setting and in clinical trials to support its efficacy and safety. Recently, the first fully substitutable generic version of GA (Glatopa ® ) was approved by the US FDA [16] , making it the only generic DMT currently available in the US market. Data to date with 7,500 patients receiving Glatopa ® indicates that the adverse events documented from launch until September 30, 2016 for Glatopa ® are consistent with what is described in the Glatopa ® PI [15, 16] .
The current review will provide an overview of the development of GA, highlighting the key early preclinical and clinical studies that led to its approval in the US, the two decades of postapproval experience with GA, subsequent development of the first approved generic version of this important MS DMT, and the cost implications of DMT generics in the MS market.
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A C C E P T E D M A N U S C R I P T thought to act as an autoantigen in MS and in EAE) will induce EAE [17] . Contrary to this hypothesis, copolymer mixtures produced were not encephalitogenic, but were observed to be protective against EAE. In particular, Cop-1 (heterogeneous mixture comprising L-alanine, Llysine, L-glutamic acid, and L-tyrosine) had the greatest activity against EAE, reducing the incidence of EAE, as well as the prevalence and severity of histological lesions [17] .
Importantly, preclinical research in other EAE models indicated that the activity of Cop-1 was not species-specific (i.e., activity demonstrated in guinea pigs, rabbits, numerous murine models, and monkeys), nor was it restricted by disease type or encephalitogen used for EAE induction [19] [20] [21] [22] .
Following its discovery and the accumulation of preclinical data supporting its use as a therapeutic agent in MS, the clinical evaluation of GA was initiated in the late 1970s [23] .
Intensive clinical research has since been conducted on GA to establish its efficacy and safety as a DMT for MS, resulting in its initial approval for RRMS in 1996 and for clinically isolated syndrome in 2009, followed by a subsequent label change to the current indication of relapsingforms of MS along with approval of a higher dose and less frequently administered version of GA in 2014 ( Fig. 1) [15, 17, [24] [25] [26] [27] [28] .
Pivotal clinical evidence in relapsing forms of multiple sclerosis
Clinical evidence from five randomized, placebo-controlled studies supported the efficacy and Finally, the multinational, phase 3 pivotal GALA trial (N=1,404) was conducted to assess a less frequently dosed three-times-a-week version of GA, administered at a higher dose (40 mg/mL) for 12 months [28] . GA reduced the risk of relapse by 34%, as well as the cumulative number of Gd-enhancing and new or newly enlarging T2 lesions at 6 and 12 months (all P=0.0001 vs.
placebo). Subsequently, the three-times-a-week, 40-mg/mL version of GA (Copaxone ® ) was approved by the FDA in early 2014 [15] .
Post-approval experience with glatiramer acetate
Extensive clinical data is available following the initial approval of Copaxone rates from baseline that was observed with GA therapy were maintained during the open-label extension (OLE) phase with no long-term safety issues [30] [31] [32] . An increased risk of neurologic disability and higher annualized relapse rates were observed in patients originally receiving placebo who switched to GA during the open-label extension phase, highlighting the importance of early treatment with GA [30, 31] . Similarly, early treatment with GA was more effective at lowering the risk of CDMS, compared with delayed treatment during the 2-year OLE phase of the PreCISe trial in CIS patients [33] .
Head-to-head clinical trials comparing GA with interferon beta-1a (REGARD trial) [34] and interferon beta-1b (BEYOND and BECOME trials) [35, 36] demonstrated that similar efficacy was observed between these first-generation DMTs with regards to clinical activity (e.g., relapse)
and MRI-assessed outcomes. Additional studies have also evaluated the effects of GA on healthrelated quality of life [37] [38] [39] [40] , as a subsequent-line therapy (i.e., previous use of interferon beta1b or following induction therapy with mitoxantrone) [41] [42] [43] [44] , and as part of combination therapy [45, 46] .
Development of Generic Versions of Glatiramer Acetate
In 2015, the US FDA approved the first generic version of GA, Glatopa ® (Momenta Pharmaceuticals), as a fully substitutable generic for all indications for which the 20-mg Copaxone ® dose is approved [16] . This approval was obtained through the FDA's Abbreviated New Drug Application (ANDA) pathway [47] using a scientific approach to demonstrate therapeutic equivalence to the innovator drug [48] .
GA is classified by the FDA as a complex mixture of polypeptides. Despite this complexity, approval was accomplished through a rigorous scientific approach to characterize Copaxone ® and thus establish equivalence between Glatopa ® and Copaxone ® , which involved assessment across four major criteria: starting materials and basic chemistry; structural signatures for polymerization, depolymerization, and purification; physicochemical properties; and biological and immunological properties [49] . First, use of the same starting materials (i.e., 4-amino acid N-
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A C C E P T E D M A N U S C R I P T 7 carboxyanhydrides), reagents (e.g., polymerization initiator), and basic chemical steps (i.e., polymerization; depolymerization and deprotection; purification) involved in synthesizing Copaxone ® demonstrated that the fundamental reaction scheme used to produce the active ingredient of generic GA injection was equivalent to that of Copaxone ® [49] . Second, structural/process signatures for each step during the chemical synthesis of GA were identified using process characterization studies; N-terminal amino acid sequence is an example of a structural signature for propagational shift during the initial polymerization step of GA synthesis [49] . Equivalence of these structural/process signatures between Glatopa ® and Copaxone ® indicated that the processes involved in the manufacture of these two drugs were equivalent [49] . [49, 50] . These assays were also employed in well-established animal models of MS (e.g., EAE), and recent findings indicated that Glatopa ® and Copaxone ® were equally effective at delaying symptom onset, disease intensity, and "immunofingerprints" [50] . In addition to these four major criteria, recent gene expression profiling through microarray analysis conducted in GAresponsive animal cell lines did not observe any significant differences in gene expression profiles (e.g., chemokine and interleukin expression levels) between Glatopa ® and Copaxone of GA and Copaxone ® [52] . This generic version of GA is currently being reviewed by the US FDA. Therefore, it is anticipated that several generic versions of GA will be available for the treatment of MS in the near future.
Cost implications of DMT generics in the US MS market
The treatment of MS with DMTs is associated with health gains, but the cost of these drugs is high [53] Therefore, the availability of additional GA generics, including 40-mg/mL generic versions, may further increase cost savings associated with the use of GA for relapsing forms of MS.
Conclusions
The first-generation DMT, GA, remains a valuable first-line treatment option for relapsing forms of MS, with over two decades of extensive clinical experience supporting its efficacy and safety.
However, the continual rising costs of DMTs (including Copaxone  The cost of GA is high, highlighting potential value of generics for treating MS.
 A rigorous scientific approach was used to lead to the first approved GA generic.
 The cost implications of generic GA in the MS market are important to understand.
